Leslie W. Kreis - Feb 27, 2024 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role
10%+ Owner
Signature
Leslie W. Kreis, Jr By: /s/ Daniel Schwarz, as attorney-in-fact
Stock symbol
LTRN
Transactions as of
Feb 27, 2024
Transactions value $
-$676,294
Form type
4
Date filed
2/29/2024, 09:54 PM
Previous filing
Jan 19, 2024
Next filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LTRN Common Stock Sale -$20.5K -4.65K -6.31% $4.40 69K Feb 27, 2024 By Bios Fund II NT, LP F1, F4, F5, F6
transaction LTRN Common Stock Sale -$33.5K -6.91K -10.01% $4.85 62.1K Feb 28, 2024 By Bios Fund II NT, LP F2, F4, F5, F6
transaction LTRN Common Stock Sale -$8.92K -1.83K -2.95% $4.87 60.3K Feb 29, 2024 By Bios Fund II NT, LP F3, F4, F5, F6
transaction LTRN Common Stock Sale -$153K -34.7K -6.31% $4.40 515K Feb 27, 2024 By Bios Fund II QP, LP F1, F4, F5, F6
transaction LTRN Common Stock Sale -$250K -51.6K -10.01% $4.85 464K Feb 28, 2024 By Bios Fund II QP, LP F2, F4, F5, F6
transaction LTRN Common Stock Sale -$66.7K -13.7K -2.95% $4.87 450K Feb 29, 2024 By Bios Fund II QP, LP F3, F4, F5, F6
transaction LTRN Common Stock Sale -$46.7K -10.6K -6.31% $4.40 158K Feb 27, 2024 By Bios Fund II, LP F1, F4, F5, F6
transaction LTRN Common Stock Sale -$76.5K -15.8K -10% $4.85 142K Feb 28, 2024 By Bios Fund II, LP F2, F4, F5, F6
transaction LTRN Common Stock Sale -$20.4K -4.19K -2.95% $4.87 138K Feb 29, 2024 By Bios Fund II, LP F3, F4, F5, F6
holding LTRN Common Stock 218K Feb 27, 2024 By Bios Fund I QP, LP F4, F5, F6
holding LTRN Common Stock 372K Feb 27, 2024 By Bios Fund I, LP F4, F5, F6
holding LTRN Common Stock 26.1K Feb 27, 2024 By BP Directors, LP F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. On February 27, 2024 each of Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $4.35 to $4.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) to (3) to this Form 4.
F2 The price reported in Column 4 is a weighted average price. On February 28, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.60 to $5.21, inclusive.
F3 The price reported in Column 4 is a weighted average price. On February 29, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $4.62 to $5.33, inclusive.
F4 Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
F5 Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F6 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 will be filed by Aaron Glenn Louis Fletcher as the designated filer.